Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for VTRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -1.243B
March 31, 2026 -203.80M
December 31, 2025 -236.40M
September 30, 2025 -228.10M
June 30, 2025 -362.40M
March 31, 2025 -467.00M
December 31, 2024 -1.420B
September 30, 2024 -1.637B
June 30, 2024 -847.90M
March 31, 2024 -425.60M
December 31, 2023 -926.10M
September 30, 2023 -97.60M
June 30, 2023 -303.50M
March 31, 2023 -974.70M
December 31, 2022 -1.331B
September 30, 2022 -758.70M
June 30, 2022 -779.60M
March 31, 2022 -1.009B
December 31, 2021 -349.20M
September 30, 2021 -877.50M
June 30, 2021 -685.50M
March 31, 2021 -1.100B
December 31, 2020 149.10M
September 30, 2020 -145.70M
June 30, 2020 -584.30M
Date Value
March 31, 2020 -24.80M
December 31, 2019 -464.40M
September 30, 2019 -132.70M
June 30, 2019 -531.80M
March 31, 2019 -40.10M
December 31, 2018 -576.20M
September 30, 2018 -224.80M
June 30, 2018 -168.50M
March 31, 2018 -121.40M
December 31, 2017 -631.70M
September 30, 2017 -423.10M
June 30, 2017 -258.80M
March 31, 2017 -572.00M
December 31, 2016 -44.70M
September 30, 2016 -530.20M
June 30, 2016 5.890B
March 31, 2016 30.50M
December 31, 2015 923.50M
September 30, 2015 -431.00M
June 30, 2015 233.00M
March 31, 2015 -109.00M
December 31, 2014 -13.70M
September 30, 2014 -26.20M
June 30, 2014 -112.90M
March 31, 2014 -114.60M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Pfizer Inc. -3.663B
Eli Lilly & Co. 8.426B
Merck & Co., Inc. 1.762B
Bristol Myers Squibb Co. -2.63B
Johnson & Johnson -8.777B